Registration Applicants in Egypt: Three Entity Types Explained

1. Key takeaways

The official Egyptian guidelines define precisely who may file a registration application: a registration applicant is an importing company, a local factory, or a scientific office. In addition, the guidelines recognize a registration applicant representative, a person delegated by the applicant to follow up all matters before the registration department. The widely circulated label of an Egyptian Registration Holder (ERH) is not EDREX terminology but established industry usage (practical estimate). Foreign manufacturers cannot submit directly; an application must be filed by one of the three recognized entity types. This makes the choice of applicant structure a commercial decision with regulatory consequences, because each of the three types carries different legal responsibilities, different documentary prerequisites, and different long-term obligations toward the EDA.

2. Legal basis

3. Expert insights

Insight 1: the three entity types map onto three different commercial structures.

The importing company is defined in the guideline as the first entity in the supply chain to import a foreign-manufactured medical device into the Arab Republic of Egypt, and it suits a trade-led entry model. The local factory is the entity manufacturing the device at premises or facilities within Egypt, and it suits a local production model. The scientific office is an EDA-licensed office that may be authorized by a manufacturer to register devices on its behalf in Egypt, and it suits a long-term brand-presence model. The legal responsibilities and continuing obligations of the three differ materially, so the entity decision should be made before dossier preparation begins, not after.

Insight 2: a scientific office is not limited to registering devices of its own parent company.

GL.CAMD.002 provides that when a scientific office registers devices produced by a company other than the company to which its parent branch belongs, it must submit three documents: a certified authorization letter issued by the legal manufacturer; a no-objection letter issued by the parent company declaring no objection to the device-owning company entrusting the registration to that scientific office; and the original power of attorney approved by the board of directors and bearing a bank-certified signature. The three-document package exists precisely because the office is acting outside its own corporate family, and any missing document halts the application at the formal check.

Insight 3: the representative system pins responsibility to a specific person.

The guideline defines the registration applicant representative as the person delegated by the applicant to follow up all matters before the registration department. Read together with Section 9, item 10 of GL.CAMD.002, which requires that dealings with the registration department be conducted under a formal power of attorney with a bank-certified (valid) signature, the framework locks down both the institutional responsibility and the personal authorization at the same time. A named, duly authorized representative with valid papers is thus a precondition of any filing, and turnover in that role should trigger an immediate document refresh.

Insight 4: a license can be transferred between an agent or distributor and a scientific office, but the documentary requirements are detailed.

Section 8 of GL.CAMD.003 governs the transfer scenario: where the scientific office license states the parent company name rather than the manufacturer name, a letter explaining the relationship between the two must be submitted; in addition, the manufacturer’s authorization letter permitting the scientific office to register the devices must be submitted, together with the parent company’s approval letter allowing the scientific office to register the devices for the benefit of the legal manufacturer. This is a pathway often mistaken for a simple change of agent. In reality it is a documented legal chain, and underestimating it is a common source of delay when distributors change.

Insight 5: the ERH label is acceptable in conversation, but official documents must return to the official terminology.

Using ERH in communication with local partners poses no difficulty, but in documents submitted to the EDA, in authorization letters, and in powers of attorney, the guideline terminology of registration applicant, together with the specific entity type, should be used. Terminology inconsistency is a formal-review risk, and a document that names a non-statutory role can trigger queries that cost weeks. (Practical estimate: ERH is established industry usage.)

4. Practical recommendations

1. Choose the entity structure before starting the dossier: trade-led entry points to the importing company, local manufacturing to the local factory, and long-term brand building warrants evaluating the scientific office.
2. Prepare the three letters early on the scientific office pathway: the manufacturer’s authorization letter, the parent company’s no-objection letter, and the board-approved power of attorney with bank-certified signature.
3. Name the registration applicant representative and execute a bank-certified power of attorney: this is the pass for all dealings with the registration department.
4. Have the authorization letter certified: complete the certification chain through the chamber of commerce, the foreign ministry, and the Egyptian embassy (practical estimate: the exact certification steps follow those listed in the current guideline).
5. Process entity changes under Section 8 of GL.CAMD.003: do not substitute a new application for the transfer, and do not assume the transfer requires no documents.
6. Use the official terminology consistently in documents: write registration applicant in external filings instead of relying on ERH alone.

5. Verification checklist

• □ Determined the registration applicant entity type (importing company / local factory / scientific office)
• □ Appointed the registration applicant representative and executed a bank-certified power of attorney
• □ On the scientific office pathway, prepared the manufacturer’s authorization letter and the parent company’s no-objection letter
• □ Completed the required certification chain for the authorization letter
• □ Used the official term registration applicant consistently in submission documents
• □ Processed the entity change under Section 8 of GL.CAMD.003

Regulatory information verified as of October 29, 2026. The entity definitions described in this article follow the current texts of EDREX: GL.CAMD.002, GL.CAMD.003, and GL.CAMD.09; the label ERH is established industry usage and is marked as a practical estimate.

• Local Egypt support: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval, and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant structure (importing company, local factory, or scientific office), preparation for Scientific Committee evaluation, advisory work on pathways for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the build-out of vigilance systems and periodic reporting.
• Service capabilities: product characterization and risk classification (devices Class I–III and IVDs Class A–D), registration and re-registration, determination of applicability of system registration and group registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.